A R T I C L E S
Evans and Starr
epoxide, isolated as the diacetate 3 (eq 1). The epoxide
derivative did not appreciably inhibit tumor cell growth, and
thus the strained C2-C20 double bond may be necessary for
the observed antitumor activity. Hexacyclinic acid displays weak
anticancer activity and, in the case of MCF-7 (GI50 ) 14 µmol),
proved to be 2 orders of magnitude less potent, further impli-
cating the C2-C20 double bond as important for the antitumor
activity of this class of compounds. While it is tempting to assign
a biologically important role to the strained bridgehead enol
ether in 1, the available examples do not rule out acetylation of
the ring-A hydroxyls as the cause of diminished activity in the
series.3
Interest in the synthesis of FR182877 has risen sharply since
its introduction due to its important biological activity as well
as its complex polycyclic architecture. Efforts by the Nakada4
and Armstrong5 groups have resulted in publications of partial
syntheses of the AB ring system and a model of the DF ring
system, respectively. The Sorensen group has published two
partial syntheses6a,b and recently a completed total synthesis6c,d
of ent-1 nearly contemporaneous with our own communication7
of the completed synthesis of 1. In addition to these reports,
other research groups are currently investigating syntheses of
FR182877.8
The unifying theme of the published approaches to 1 has been
the disconnection of ring-B using a Diels-Alder cycloaddition
transform. The further disconnection of ring-D through a hetero-
Diels-Alder cycloaddition was recognized both by us and by
Sorensen,6a ultimately leading to our independent development
of similar syntheses of FR182877 based on a stereocontrolled
cascade of transannular Diels-Alder cycloaddition events. In
this Article, we provide a complete account of the design and
realization of a transannular cycloaddition strategy leading to
the completion of a total synthesis of the natural antipode of
FR182877. In addition, we describe our efforts to utilize the
tools of computational modeling to develop an understanding
of the stereochemical outcome of the Diels-Alder cycloaddition
cascade.
The hexacyclic structure of 1 incorporates a bridgehead enol
ether and an embedded cyclohexene ring, suggesting its bio-
synthetic origin from a sequence of intramolecular Diels-Alder
cycloaddition events. This idea was initially proposed by
Sorensen in 1999 and is further supported by the work of Zeeck
who isolated isotopically labeled 2 from Streptomyces cultures
inoculated with 13C-labeled acetate and propionate to establish
the connectivity of a supposed polyketide chain precursor to
Figure 1. Polyketide origin of hexacyclinic acid.
hexacyclinic acid (Figure 1). This allowed mapping of acetate
and propionate subunits to their respective locations in the
skeleton of 2 and proved to be consistent with a biosynthetic
pathway including Diels-Alder cycloadditions for generating
rings B and D.
The structures of 1 and 2 were established by standard
spectroscopic methods coupled with X-ray crystallographic
analysis, and the absolute configurations were determined in
each case by the Mosher ester method. However, on the basis
of our own analysis of the reported data for the FR182877
Mosher esters,9 we suspected that its absolute configuration had
been incorrectly assigned. Consequently, we designed a syn-
thesis targeting the configuration of hexacyclinic acid, confident
that, in the final analysis, it would prove to be homologous with
(-)-FR182877. Our presumption was later confirmed with the
publication of a correction in 2002.1e
Synthesis Plan. The structural relationship between FR182877
and hexacyclinic acid prompted us to develop a synthesis plan
targeting an advanced intermediate bearing the common ster-
eochemical features and peripheral functionality of both natural
products. The pivotal transformations associated with both
syntheses are the sequential transannular Diels-Alder10 and
hetero-Diels-Alder11 cycloadditions forming rings B and D,
respectively (Scheme 1). Because the ring-B Diels-Alder
reaction would be the initiating reaction (see Molecular Model-
ing section), the endo-TS transition state would afford the
FR182877 ring system while the diastereomeric exo-TS transi-
tion state would afford the hexacyclinic acid ring system. We
designed macrocycle 5, carrying a bromine substituent at C11,
so that it might serve as a common intermediate for the synthesis
of either natural product. In so doing, the syntheses of 1 and 2
could be unified under the common advanced intermediate 5.
Macrocycle 5 was envisioned to arise from a â-keto ester
alkylation and Suzuki12 cross coupling of the illustrated
C3-C10 and C11-C20 fragments. Each fragment could in turn
be derived from auxiliary-controlled enolborane syn-aldol
(3) The acetylated pachyclavulariaenones D-F are not cytotoxic, in contrast
to potent pachyclavulariaenone G having all three hydroxyls free. Suscep-
tible cell lines were P-388 and HT-29; however, no comment is made on
mechanism of action. See: Wang, G.-H.; Sheu, J.-H.; Duh, C.-Y.; Chiang,
M. Y. J. Nat. Prod. 2002, 65, 1475. A comparison of MM2 minimized
space-filling models of pachyclavulariaenone G and (-)-FR182877 using
Spartan showed considerable homology in size, shape, and disposition of
polar functionality between the two natural products (Evans and Starr,
unpublished).
(9) Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. J. Am. Chem. Soc.
1991, 113, 4092. See also ref 1d for Mosher analysis data on (-)-FR182877.
(10) (a) For a review of TADA reactions, see: Marsault, E.; Toro, A.; Nowak,
P.; Deslongchamps, P. Tetrahedron 2001, 57, 4243. (b) For a recent
example, see also: Longithorone A: Layton, M. E.; Morales, C. A.; Shair,
M. D. J. Am. Chem. Soc. 2002, 124, 773. (c) Use of a bromodiene in TADA
reaction, see: Roush, W. R.; Koyama, K.; Curtin, M. L.; Moriarty, K. J.
J. Am. Chem. Soc. 1996, 118, 7502.
(4) Suzuki, T.; Nakada, M. Tetrahedron Lett. 2002, 43, 3263.
(5) Armstrong, A.; Goldberg, F. W.; Sandham, D. A. Tetrahedron Lett. 2001,
42, 4585.
(6) (a) Vanderwal, C. D.; Vosberg, D. A.; Weiler, S.; Sorensen, E. J. Org.
Lett. 1999, 1, 645. (b) Vanderwal, C. D.; Vosberg, D. A.; Sorensen, E. J.
Org. Lett. 2001, 3, 4307. (c) Vosburg, D. A.; Vanderwal, C. D.; Sorensen,
E. J. J. Am. Chem. Soc. 2002, 124, 4552. (d) Vanderwal, C. D.; Vosberg,
D. A.; Weiler, S.; Sorensen, E. J. J. Am. Chem. Soc. 2003, 125, 5393.
(7) Evans, D. A.; Starr, J. T. Angew. Chem., Int. Ed. 2002, 41, 1787.
(8) The following investigators have indicated their efforts toward FR182877
.htm).
(11) (a) For this type of hetero-[4+2] cycloaddition, see: Shin, K.; Moriya,
M.; Ogasawara, K. Tetrahedron Lett. 1998, 39, 3765. (b) Takano, S.; Satoh,
S.; Ogasawara, K. J. Chem. Soc., Chem. Commun. 1988, 59. (c) Takano,
S.; Satoh, S.; Ogasawara, K.; Aoe, K. Heterocycles 1990, 30, 583. (c)
Yamauchi, M.; Katayama, S.; Baba, O.; Watanabe, T. J. Chem. Soc., Chem.
Commun. 1983, 281.
(12) For a review, see: Miyaura, N.; Suzuki, A. Chem. ReV. 1995, 95, 2457.
9
13532 J. AM. CHEM. SOC. VOL. 125, NO. 44, 2003